As of June 15, 2025, Beijing SL Pharmaceutical Co Ltd (002038.SZ) reports a Gross Margin of 67.89%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Beijing SL Pharmaceutical Co Ltd's Gross Margin
Over recent years, Beijing SL Pharmaceutical Co Ltd's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 67.89% |
| 2023-12-31 | 81.46% |
| 2022-12-31 | 85.05% |
| 2021-12-31 | 84.89% |
| 2020-12-31 | 85.31% |
This slight upward trend highlights how Beijing SL Pharmaceutical Co Ltd manages its operational efficiency and pricing power over time.
Comparing Beijing SL Pharmaceutical Co Ltd's Gross Margin to Peers
To better understand Beijing SL Pharmaceutical Co Ltd's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Beijing SL Pharmaceutical Co Ltd (002038.SZ) | 67.89% |
| Xiamen Amoytop Biotech Co Ltd (688278.SS) | 93.49% |
| Beijing Balance Medical Technology Co Ltd (688198.SS) | 88.34% |
| Amoy Diagnostics Co Ltd (300685.SZ) | 84.75% |
| Staidson Beijing BioPharmaceuticals Co Ltd (300204.SZ) | 80.83% |
| Guanhao Biotech Co Ltd (300238.SZ) | 79.12% |
Compared to its competitors, Beijing SL Pharmaceutical Co Ltd's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.